Regen Biopharma FY2024 net loss $867k, revenue $237k; cash only $716

Regen BioPharma Inc

2024-09-30 EPS reported -$0.21 revenue$236,560

Total revenues of $236,560 (incl. $110k related party); operating loss of $418,189.
Net loss of $867,252; basic & diluted EPS of ($0.21) on 4.1M weighted avg shares.
Cash and cash equivalents at Sept 30, 2024: just $716; total assets $177,611.
Total liabilities $5.37M vs. stockholders deficit ($5.19M); accumulated deficit $20.6M.
Company remains development-stage; no FDA approvals for any product candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.